| Name | Title | Contact Details |
|---|
Lanx is one of the largest and fastest growing private spine companies in the U.S. The Company was founded by a team of experienced medical device professionals and engineers in 2003 to improve the quality of spine care and provide surgeons with innovative products.
We`re Villa Healthcare, and we make people better. Of course, we`re focused on quality care and good outcomes. But we`re here to do so much more. At Villa, we offer the very best in post-acute and long-term care. Our focus is providing exceptional clinical services by people who truly care, in an environment that promotes healing and wellness. Villa`s leadership has a vision of rising above the status quo—of never settling, and of shattering the old image of this industry. We`ve always wanted to be a part of something greater, and we`ve made that a reality by both making people better and by creating and sharing opportunities. We currently have 22 facilities in four different states*. As Villa has grown, we have redoubled our efforts to ensure that the Villa experience is the same at every location. By extensively renovating our centers and hiring the best people we can, we are making our mark in the world of healthcare. It`s how Villa makes people better.
Cigna-HealthSpring is a leading health service company committed to helping our nation`s Medicare and Medicaid beneficiaries live healthier, more active lives through personalized, affordable and easy-to-use health care solutions. Cigna-HealthSpring key products include Medicare Advantage, Medicare Prescription Drug Coverage, Medicaid and other health service products.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
SouthStar Health Group is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.